Blood Cancer Clinical Trials & Research at St. Joseph Health Medical Group

Chronic lymphocytic leukemia and multiple myeloma, blood cancers, represent a large group of different malignancies. This group includes cancers of the bone marrow, blood, and lymphatic system, which includes lymph nodes, lymphatic vessels, tonsils, thymus, spleen, and digestive tract lymphoid tissue. Leukemia and myeloma, which start in the bone marrow, and lymphoma, which starts in the lymphatic system, are the most common types of blood cancer. What causes these cancers is not known.

St. Joseph Health Medical Group is currently enrolling patients for the following blood cancer clinical trials:

Leukemia

Novel Btk Inhibitor for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL) Clinical Trial

  • All patients receive treatment: ACP196 (Btk Inhibitor) or Ibrutinib.
  • Patients need to have finished at least one prior treatment for CLL.
  • Main study doctor (Principal Investigator): Jarrod Holmes, MD.
  • For more information, please contact the lead coordinator, Catherine Hollister, at (707) 521-3808 or Catherine.Hollister@stjoe.org.

A Disease Registry for Patients with Chronic Lymphocytic Leukemia (CLL)

  • Study name: informCLL™.
  • There is no treatment involved with this study.
  • Patients complete questionnaires to help physicians better understand current treatment patterns for CLL in the real-world setting.
  • Main study doctor (Principal Investigator): Wes Lee, MD.
  • For more information, please contact the lead coordinator, Diego Martinez, at (707) 521-3810 or Diego.Martinez@stjoe.org.

Blood Cancer: Multiple Myeloma

Multiple Myeloma (MM) RegistryStudy

  • Study name: INSIGHT-MM.
  • There is no treatment involved with this study.
  • Patients complete questionnaires to help physicians better understand current treatment patterns for MM in the real-world setting.
  • Main study doctor (principal investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Diego Martinez, at (707) 521-3810 or Diego.Martinez@stjoe.org.

Myelofibrosis (MF) and Essential Thrombocythemia (ET) Registry

  • Study name: MOST.
  • There is no treatment involved with this study.
  • Patients complete questionnaires to help physicians better understand current treatment patterns for MF and ET in the real-world setting.
  • Main study doctor (principal investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Catherine Hollister, at (707) 521-3808 or Catherine.Hollister@stjoe.org.

Our Locations